The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...
Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) constitutes a frequent problem, especially in athletes showing ventricular arrhythmias with left bundle branch block ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback